Corporate Snapshot: Changzhou Qianhong Biopharm and Market Context
In the latest trading session that concluded at 11:41 AM Central Europe on Friday, 23 October 2026, Changzhou Qianhong Biopharm (002550.SZ) exhibited a flat performance, with its price unchanged over the 24‑hour period. The Shanghai‑listed company is currently trading at CNH 6.27 per share on major exchanges, a price that sits below its simple moving average of the past 200 days, which is CNH 6.52.
Market Capitalisation and Trading Volume
The enterprise has a market capitalisation of approximately CNH 1.1 billion. During the most recent 24‑hour window, the trading activity amounted to roughly CNH 41.1 million, a modest figure relative to the total 1.3 billion shares outstanding.
Historical Price Performance
Over the preceding month, the stock has experienced a decline of 5.36 %. In terms of long‑term perspective, Changzhou Qianhong Biopharm’s 52‑week high of CNH 9.44 was reached on 11 March 2025, while its 52‑week low of CNH 5.58 was recorded on 22 June 2026. These extremes illustrate a relatively narrow trading range, suggesting a certain level of price stability despite recent volatility.
Comparative Overview of Peer Stocks
The same trading day saw several other Chinese and Hong Kong listed companies maintaining flat performance or experiencing a decline:
| Ticker | Current Price (CNH/HKD) | Market Capitalisation (CNH/HKD) | Recent Performance | Notes |
|---|---|---|---|---|
| Beijing Yuanliu Hongyuan E (603267.SS) | CNH 42.38 | CNH 1.3 billion | Flat 0 % | Operates in the semiconductor‑materials sector; part of a broader rally in the MLCC market. |
| Shanxi Lanhua Sci‑tech (600123.SS) | CNH 6.36 | CNH 1.3 billion | Flat 0 % | No significant recent events reported. |
| PCI‑LT (600728.SS) | CNH 4.55 | CNH 1.3 billion | Flat 0 % | High price‑earnings ratio of 135.44, indicating premium valuation. |
| CSPC Hunan Jingfeng Pharma (000908.SZ) | CNH 5.35 | CNH 1.3 billion | Flat 0 % | Subject to new regulatory guidelines on major‑shareholder sale restrictions. |
| Pegbio‑H (2565.HK) | HKD 3.52 | HKD 1.4 billion | Down 7.73 % | The decline reflects broader market sentiment in Hong Kong’s biotech segment. |
Regulatory Developments Affecting CSPC Hunan Jingfeng Pharma
The Chinese securities regulator has introduced stricter enforcement of stock‑sale restrictions for major shareholders, with the guidelines slated for effect in December. Key elements include:
- Clearer fine thresholds for non‑compliance.
- Joint accountability for coordinated sale arrangements.
- Expanded scrutiny of acquisition‑stage transactions.
These measures aim to protect smaller investors while preserving legitimate exit opportunities for institutional shareholders, thereby enhancing market transparency.
Company Profile: Changzhou Qianhong Biopharm
- Industry: Pharmaceutical, specializing in the development, production, and sale of lyophilized powders, injection powders, parenteral solutions, tablets, capsules, granules, and raw medicines.
- Key Products: Bulk drugs and formulations of heparin sodium, l‑asparaginase, and kallidinogenase.
- Headquarters: Changzhou, China.
- Listing: Shenzhen Stock Exchange (Ticker: 002550.SZ).
- IPO: 18 February 2011.
- Website: www.qhsh.com.cn
The company’s focus on essential pharmaceuticals places it within a critical sector of China’s health‑care supply chain. Its stable trading performance, coupled with a moderate valuation relative to its peers, suggests a cautiously optimistic outlook for investors seeking exposure to the domestic pharma market.